OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, December 04, 2012

Reasons cancer increases with age are not obvious - Cancer



Reasons cancer increases with age are not obvious - Printz - 2012 - Cancer - Wiley Online Library

Researchers at the University of Colorado Cancer Center in Denver have argued against the traditional belief that older people develop cancer because they accumulate more cancer-causing mutations. Instead, they argue that it is due to changing features of tissue as people age.
Their review, published in Oncogene, notes that by the time people stop growing in their teens, they have already developed many of the mutations they will acquire during their lives.1 Lead author James DeGregori, PhD, a professor of molecular biology at the University of Colorado, says there is a mismatch between the mutation curve and the cancer curve. If cancer were to develop based on 5 or 6 mutations, cancer rates would be much higher in those aged 20 years, when the mutation rate is highest, but that is not the case, he says.
Dr. DeGregori adds that even healthy tissues are full of oncogenic mutations, which are much more common than the cancers associated with them. Furthermore, he points out that introducing oncogenes into mice stem cells theoretically should help rather than hurt the cells' survival; however, the cells that harbor oncogenes tend to get weeded out.
Rather than gathering mutations that cause cancer, what happens as people age is that the mechanisms that help young adults fight cancer begin to deteriorate. Healthy cells are optimized for the conditions of young, healthy tissue. Those cells are able to tackle those cells with cancerous mutations but, as the tissue ages, mutations can help a cancer cell adapt in ways that a healthy cell can not, he says.
Reference
  • 1
    DeGregori J. Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age? [published online ahead of print July 2, 2012]. Oncogene. doi: 10.1038/onc.2012.281.

Prohibitive Medicare Reimbursement May Restrict Hospice Enrollment in Patients Requiring High-Cost Care



Prohibitive Medicare Reimbursement May Restrict Hospice Enrollment in Patients Requiring High-Cost Care

Monday, December 03, 2012

(France) A Study of Avastin (Bevacizumab) in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Cancer, Initially Unresectable - Full Text View - ClinicalTrials.gov



A Study of Avastin (Bevacizumab) in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Cancer, Initially Unresectable - Full Text View - ClinicalTrials.gov

Ovacome (UK) Ovarian cancer patients need improved services - Stocksbridge - Local News - Postcode Gazette



Ovarian cancer patients need improved services - Stocksbridge - Local News - Postcode Gazette

New Cancer Journal Is Sign of the Times - Cancer Immunology Research



New Cancer Journal Is Sign of the Times


"Clinicians and researchers interested in the burgeoning field of cancer immunology have a new source of information.
The peer-reviewed Cancer Immunology Research will publish original research on advances in the field, according to its sponsor, the American Association for Cancer Research (AACR).
"Recent clinical successes have validated the longstanding idea that therapeutic manipulation of the immune system may achieve meaningful antitumor effects," said Glenn Dranoff, MD, the founding editor-in-chief, in a press statement. He is professor of medicine at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts....

Study Evaluating the Helical Ureteral Stent - Full Text View - ClinicalTrials.gov



Study Evaluating the Helical Ureteral Stent - Full Text View - ClinicalTrials.gov

Detailed Description:
Ureteral stents have been used for many years for a variety of clinical indications. Many surgeons routinely use ureteral stents after the endourologic removal of stones to facilitate in urine passage and facilitate excretion of any left over stones. There is a multitude of literature that reveals that most patients find ureteral stents to be uncomfortable. This discomfort often causes pain severe enough that patients anxiously anticipate stent removal, and often request early stent removal, and/or require use of pain medications that have many side effects and cause further discomfort to these patients.....

The Medicalization of Modern Life | The Health Care Blog (grief....)



The Medicalization of Modern Life | The Health Care Blog
 By

" This is the saddest moment in my 45 year career of studying, practicing, and teaching psychiatry.
The Board of Trustees of the American Psychiatric Association has given its final approval to a deeply flawed DSM 5 containing many changes that seem clearly unsafe and scientifically unsound. My best advice to clinicians, to the press, and to the general public – be skeptical and don’t follow DSM 5 blindly down a road likely to lead to massive over-diagnosis and harmful over-medication.
Just ignore the ten changes that make no sense......

American Society of Clinical Oncology issues annual report on state of clinical cancer science



American Society of Clinical Oncology issues annual report on state of clinical cancer science

Download a fully interactive copy of the Clinical Cancer Advances 2012 report at www.cancerprogress.net/cca.
About the Report
Clinical Cancer Advances was compiled and edited under the guidance of 21 renowned experts in specific fields of cancer research. The editors reviewed research published in peer-reviewed scientific or medical journals and presented at major scientific meetings over a one-year period (October 2011-September 2012). The 2012 CCA features a total of 87 studies, 17 of which are considered major, meaning they represent research results that are practice-changing, published in a peer-reviewed journal, and/or reports on treatments that received U.S. Food and Drug Administration (FDA) approval in the past year. The CCA is intended for anyone with an interest in cancer care, including, patients, caregivers, concerned family and friends of cancer patients, oncologists and other medical professionals, policymakers, and cancer advocacy organizations.

The report and additional resources are available at www.cancerprogress.net/cca and has been published online in the Journal of Clinical Oncology (www.jco.org).

date of publication 1942 (NOT a typo): PRIMARY PAPILLARY CARCINOMA OF THE URETER (Lynch Syndrome patients)



Read before the Section on Urology, at the Seventy firstAnnual Session of the California Medical Association,Del Monte, May 3-6, 1942

Ovarian Sertoli-Leydig cell tumor: a report of seven cases and a review of the literature (paywalled)




Ovarian Sertoli-Leydig cell tumor: a report of seven cases and a review of the literature.

Journal

Gynecol Endocrinol. 2012 Nov 23

Abstract

The aim of this study was to investigate the clinicopathologic features, treatment and outcome of seven patients with an ovarian Sertoli-Leydig cell tumor (SLCT). Five patients presented with feminization, two with accompanying virilization. One presented with amenorrhea alone. Three of the five patients showing feminization symptoms had endocrine-related diseases. Histologically, five tumors were well differentiated, the other two were poorly differentiated. The latter two patients were misdiagnosed as having an ovarian epithelial carcinoma or granulosa cell tumor from frozen sections. Immunohistochemistry showed that the tumors were calretinin-positive in two patients and one was inhibin-positive. Four patients underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy(TAH/BSO) and two were treated by unilateral salpingo-oophorectomy. Among them, two patients received adjuvant chemotherapy. Six patients were free of disease in a follow-up of 2-34 years and one achieved a pregnancy. The remaining patient recurred 4 years later. Feminization as well as virilization might provide important clues for a preoperative diagnosis. Histological misdiagnosis is probable in poorly differentiated tumors. Conservative surgery including retention of fertility can be considered. However, the tendency for recurrence in poorly differentiated tumors should be considered.

Diabetes Drug May Boost Ovarian Ca Survival (metformin)



Diabetes Drug May Boost Ovarian Ca Survival

"The first-line diabetes drug metformin may have a role in ovarian cancer treatment, researchers found.....

open access: Advances in oncologic imaging (breast, colon and rectum, lung, prostate, non-Hodgkin lymphoma)



Advances in oncologic imaging  A Cancer Journal for Clinicians

NCI Dictionary of Cancer Terms - "warm ischemia time" (medical terms u need 2 know)



NCI Dictionary of Cancer Terms - National Cancer Institute

warm ischemia time  listen  (… is-KEE-mee-uh …)


  In surgery, the time a tissue, organ, or body part remains at body temperature after its blood supply has been reduced or cut off but before it is cooled or reconnected to a blood supply.

open access: The current status of robotic oncologic surgery 2012 A Cancer Journal for Clinicians



The current status of robotic oncologic surgery

open access: Hypnosis for cancer care: Over 200 years young



Hypnosis for cancer care: Over 200 years young

Cognitive deficits are usually mild in patients with breast cancer after chemotherapy CA: A Cancer Journal for Clinicians



Cognitive deficits are usually mild in patients with breast cancer after chemotherapy CA: A Cancer Journal for Clinicians

Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers



Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers

Saturday, December 01, 2012

Who fakes cancer on the Internet? Women Washington Post by Donna Trussell (author/writer/ovarian cancer survivor)



Who fakes cancer on the Internet? Women

U.S. Senate approves Leonard Lance's Cancer Research Act | NJ.com



U.S. Senate approves Leonard Lance's Cancer Research Act | NJ.com

"The Recalcitrant Cancer Research Act would help the National Cancer Institute’s efforts to improve prevention, diagnosis and treatment of cancers with high mortality rates. Research advancements in the fight against pancreatic, lung, liver, and ovarian cancers have lagged behind gains made in fighting all other cancers, which have improved from 50 to 67 percent in the last 40 years."

Evaluation of Risk Factors for Venous Thromboembolism in Chinese Women With Epithelial Ovarian Cancer.



Evaluation of Risk Factors for Venous Thromboembolism in Chinese Women With Epithelial Ovarian Cancer.

Source

*Ovarian Cancer Program, Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China; and †Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI.

Abstract

OBJECTIVE:

Venous thromboembolism (VTE) is a life-threatening complication that often occurs in ovarian tumors. However, the risk factors for VTE are still undetermined.

METHODS:

We retrospectively analyzed VTE occurrence and its potential risk factors in 254 Chinese patients with ovarian tumor at Fudan University Cancer Hospital from July 2007 to June 2011.

RESULTS:

The VTE incidence was 7.1% (13/183) in epithelial ovarian cancer (EOC), and no VTE was found in ovarian borderline or benign tumor. D-dimer levels were significantly higher in EOC than in ovarian benign and borderline tumors. Furthermore, D-dimer levels increased with the advancement of EOC stages. Correlation analysis suggested that D-dimer levels were well correlated with platelet counting (PLT), prothrombin time (PT), white blood cell counting (WBC), cancer antigen (CA) 125, and CA153. Univariate logistic regression analysis found that D-dimer levels greater than 788 μg/L, PLT levels greater than 261 × 10/L, PT greater than 11.7 seconds, CA125 greater than 760 U/mL, and ascites greater than 1500 mL are risk factors for VTE in EOC. Moreover, multivariate analysis grouped primary EOC, low differentiated grade, D-dimer greater than 788 μg/L, PT greater than 11.7 seconds, and CA125 greater than 760 U/mL as prediction factors for VTE.

CONCLUSIONS:

In addition to D-dimer and ascites, high levels of PLT, PT, and CA125, which are highly correlated with D-dimer, are independent risk factors for VTE.

Considerations in the Surgical Management of Ovarian Cancer in the Elderly



Considerations in the Surgical Management of Ovarian Cancer in the Elderly.

Abstract

OPINION STATEMENT: Elderly patients with advanced epithelial ovarian cancer present a complex treatment dilemma. On the one hand, patients can be treated with primary debulking surgery to achieve the ideal oncologic outcomes but at the expense of risk of surgical morbidity and mortality. On the other hand, they can be treated with alternative, less morbid approaches, reducing toxicity, but sacrificing the survival benefits of low residual disease by surgical cytoreduction. Retrospective studies have attempted to identify risk factors for poor surgical outcome. Although there is no consensus to define "elderly" or "frail," current evidence identifies age, performance status, nutritional status, and surgical complexity as major risk factors for surgical morbidity. Accepting the shortcomings of these retrospective data, candidates for primary debulking surgery can be assessed for risk of surgical morbidity. Age is likely a contributor to morbidity, particularly in the face of comorbid conditions. Clinicians should strive to treat elderly patients with a standard approach of primary debulking surgery and adjuvant chemotherapy when healthy and in the absence of other risk factors. Elderly patients with the following are poor surgical candidates and an alternative treatment approach should be considered: poor nutritional status (characterized by serum albumin <3.0 g/dL), or poor performance status (ASA ≥3), and stage IV disease. Several of these factors are modifiable by treating the underlying cancer. These patients should be treated with two to three cycles of neoadjuvant chemotherapy and reassessed for surgical debulking. Patients with improvement in their nutritional or performance status can undergo interval debulking with the goal to resect all visible disease.

Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin



Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin.

Abstract

AIM:

To assess the efficacy and safety of the combination of pegylated liposomal doxorubicin (PLD) and carboplatin in patients with recurrent epithelial ovarian carcinoma (ROC), following disease progression on single agent PLD.

METHODS:

An analysis of the medical records of 10 patients with ROC, treated in our institution with a combination of PLD and carboplatin following progression on single-agent PLD therapy was performed. The median age was 59.1 years (range, 45 to 77 years). All diagnoses were histological-proven. Eight of the 10 patients were platinum-resistant. Following disease progression on single-agent PLD treatment, carboplatin area under the curve (AUC)-5 was added to PLD in all 10 patients. In order to assess disease status, Ca-125 was assessed before each PLD/carboplatin treatment. Relative changes in Ca-125 values were calculated, and response defined as a greater than 50% reduction in Ca-125 from baseline. Radiographic studies were re-evaluated and responses to therapy based on computer tomography (CT) scans carried out on a regular basis every 2-3 mo in each patient. Statistical analysis was performed using SPSS (V19).

RESULTS:

A median of 10 cycles (range, 2-26) of the carboplatin-PLD combination was given. Of the 10 treated patients, 6 had > 50% reduction in Ca-125 levels from baseline, 4 of these had a partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and the other 2 patients had no measurable disease. In a further 2 patients with a best response of disease stabilization and < 50% reduction of Ca-125 levels, one had progression of disease after 26 cycles, and the second progressed with brain metastases following 12 cycles. Seven of the eight patients who were platinum-resistant showed evidence of clinical benefit on carboplatin-PLD combination therapy; 5 of these had > 50% reduction in Ca-125 level, 4 also showed a partial response on CT scan. The treatment was generally well-tolerated by the patients.

CONCLUSION:

Addition of carboplatin to PLD, after disease progression on single-agent PLD therapy, is both effective and safe in patients with ROC, even in those with Platinum-resistant disease.

Extremely elevated CA-125 in benign ovarian disease due to stretch of the peritoneum - BMJ Case Reports



Extremely elevated CA-125 in benign ovarian disease due to stretch of the peritoneum BMJ Case Reports

Summary

Serum concentrations of CA-125 are rarely elevated beyond 1000 U/ml in benign conditions of the ovary in postmenopausal women. In this report, the authors present an unusual case of a 78-year-old woman with an extremely elevated CA-125 concentration of 2897 U/ml without the presence of a malignancy, ascites or pleural effusion. Imaging revealed a large intra-abdominal cystic mass with irregular solid deviations on CT scan, most likely arising from an ovary. Exploratory laparotomy was performed with suspicion of ovarian cancer but histopathological analysis revealed benign serous cystic adenofibroma. This case report highlights the diagnostic challenge of extremely increased levels of CA-125 in postmenopausal women. A possible explanation for this CA-125 elevation could be the mechanical stretch of the peritoneum.

STK11 - Wikipedia, the free encyclopedia



STK11 - Wikipedia, the free encyclopedia

paywalled: Inherited Pancreatic Cancer Syndromes : The Cancer Journal



Inherited Pancreatic Cancer Syndromes : The Cancer Journal

 Abstract

Pancreatic cancer remains one of the most challenging of all cancers. Genetic risk factors are believed to play a major role, but other than genes coding for blood group, genetic risks for sporadic cases remain elusive. However, several germline mutations have been identified that lead to hereditary pancreatic cancer, familial pancreatic cancer, and increased risk for pancreatic cancer as part of a familial cancer syndrome. The most important genes with variants increasing risk for pancreatic cancer include BRCA1, BRCA2, PALB2, ATM, CDKN2A, APC, MLH1, MSH2, MSH6, PMS2, PRSS1, and STK11. Recognition of members of high-risk families is important for understanding pancreatic cancer biology, for recommending risk reduction strategies and, in some cases, initiating cancer surveillance programs. Because the best methods for surveillance have not been established, the recommendation to refer at-risk patients to centers with ongoing research programs in pancreatic cancer surveillance is supported.